Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection

J Nunes; M Naymark; L Sauer; A Muhammad; H Keun; J Sturge; J Stebbing; J Waxman; D Pchejetski

doi:10.1038/bjc.2012.14

Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection

J Nunes, M Naymark, L Sauer, A Muhammad, H Keun, J Sturge, J Stebbing, J Waxman, D Pchejetski

Research output: Contribution to journal › Article › peer-review

48 Citations (Scopus)

Abstract

Current markers available for screening normal populations and for monitoring prostate cancer (PCa) treatment lack sensitivity and selectivity. Sphingosine-1-phosphate (S1P) is a circulating lipid second messenger involved in cell growth and migration, the immune response, angiogenesis, and malignant transformation.

Original language	English
Pages (from-to)	909-915
Number of pages	7
Journal	British Journal of Cancer
Volume	106
Issue number	5
DOIs	https://doi.org/10.1038/bjc.2012.14
Publication status	Published - 28 Feb 2012

Keywords

Anemia
Cell Line, Tumor
Disease Progression
Early Detection of Cancer
Erythrocytes
Humans
Lysophospholipids
Male
Phosphotransferases (Alcohol Group Acceptor)
Prognosis
Prostate-Specific Antigen
Prostatic Neoplasms
Sphingosine
Tumor Markers, Biological

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2012.14

Cite this

@article{4764c2308cc14b298435b4b77af27664,

title = "Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection",

abstract = "Current markers available for screening normal populations and for monitoring prostate cancer (PCa) treatment lack sensitivity and selectivity. Sphingosine-1-phosphate (S1P) is a circulating lipid second messenger involved in cell growth and migration, the immune response, angiogenesis, and malignant transformation.",

keywords = "Anemia, Cell Line, Tumor, Disease Progression, Early Detection of Cancer, Erythrocytes, Humans, Lysophospholipids, Male, Phosphotransferases (Alcohol Group Acceptor), Prognosis, Prostate-Specific Antigen, Prostatic Neoplasms, Sphingosine, Tumor Markers, Biological",

author = "J Nunes and M Naymark and L Sauer and A Muhammad and H Keun and J Sturge and J Stebbing and J Waxman and D Pchejetski",

year = "2012",

month = feb,

day = "28",

doi = "10.1038/bjc.2012.14",

language = "English",

volume = "106",

pages = "909--915",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection

AU - Nunes, J

AU - Naymark, M

AU - Sauer, L

AU - Muhammad, A

AU - Keun, H

AU - Sturge, J

AU - Stebbing, J

AU - Waxman, J

AU - Pchejetski, D

PY - 2012/2/28

Y1 - 2012/2/28

N2 - Current markers available for screening normal populations and for monitoring prostate cancer (PCa) treatment lack sensitivity and selectivity. Sphingosine-1-phosphate (S1P) is a circulating lipid second messenger involved in cell growth and migration, the immune response, angiogenesis, and malignant transformation.

AB - Current markers available for screening normal populations and for monitoring prostate cancer (PCa) treatment lack sensitivity and selectivity. Sphingosine-1-phosphate (S1P) is a circulating lipid second messenger involved in cell growth and migration, the immune response, angiogenesis, and malignant transformation.

KW - Anemia

KW - Cell Line, Tumor

KW - Disease Progression

KW - Early Detection of Cancer

KW - Erythrocytes

KW - Humans

KW - Lysophospholipids

KW - Male

KW - Phosphotransferases (Alcohol Group Acceptor)

KW - Prognosis

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - Sphingosine

KW - Tumor Markers, Biological

U2 - 10.1038/bjc.2012.14

DO - 10.1038/bjc.2012.14

M3 - Article

C2 - 22315056

SN - 0007-0920

VL - 106

SP - 909

EP - 915

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 5

ER -